Cargando…
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials
Most clinical trials evaluating COVID-19 therapeutics include assessments of antiviral activity. In recently completed outpatient trials, changes in nasal SARS-CoV-2 RNA levels from baseline were commonly assessed using analysis of covariance (ANCOVA) or mixed models for repeated measures (MMRM) wit...
Autores principales: | Moser, Carlee B, Chew, Kara W, Giganti, Mark J, Li, Jonathan Z, Aga, Evgenia, Ritz, Justin, Greninger, Alexander L, Javan, Arzhang Cyrus, Daar, Eric S, Currier, Judith S, Eron, Joseph J, Smith, Davey M, Hughes, Michael D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055451/ https://www.ncbi.nlm.nih.gov/pubmed/36993419 http://dx.doi.org/10.1101/2023.03.13.23287208 |
Ejemplares similares
-
881. Nasal and Plasma SARS-CoV-2 RNA Levels Predict Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19
por: Li, Yijia, et al.
Publicado: (2022) -
Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19
por: Moser, Carlee, et al.
Publicado: (2022) -
878. Association between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death for Non-Hospitalized Adults with Mild-to-Moderate COVID-19
por: Giganti, Mark, et al.
Publicado: (2022) -
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials
por: Bender Ignacio, Rachel A., et al.
Publicado: (2023) -
LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
por: Evering, Teresa H, et al.
Publicado: (2021)